Allergy:慢性鼻炎的内源性类型研究

2018-11-09 AlexYang MedSci原创

慢性鼻炎(CR)目前被认为是一种综合症状,并包括几种不同的内源性类型。最近,有研究人员鉴定了CR的内源性类型分类,并调查了与不同类型相关的炎症模式情况。研究总共包括了259名CR患者和20名对照,并在中国CR患者群体中鉴定了6个内源性CR类型。分类1(38.6%)患者被诊断为过敏性鼻炎且不患有哮喘,分类2(13.5%)被诊断为过敏性鼻炎且患有哮喘;并且均伴随着局部嗜酸性粒细胞的阳性结果和高水平的局

慢性鼻炎(CR)目前被认为是一种综合症状,并包括几种不同的内源性类型。最近,有研究人员鉴定了CR的内源性类型分类,并调查了与不同类型相关的炎症模式情况。

研究总共包括了259名CR患者和20名对照,并在中国CR患者群体中鉴定了6个内源性CR类型。分类1(38.6%)患者被诊断为过敏性鼻炎且不患有哮喘,分类2(13.5%)被诊断为过敏性鼻炎且患有哮喘;并且均伴随着局部嗜酸性粒细胞的阳性结果和高水平的局部血清lgE。相似的,分类3患者(18.6%)被诊断为非过敏性鼻炎但患有嗜酸性粒细胞综合症(NARES),且不伴随哮喘,分类5(5%)是具有NARES和哮喘的患者;这2种分类的患者均具有阳性局部嗜酸粒细胞结果和局部血清lgE阴性结果。分类4是具有局部过敏性鼻炎(LAR)和具有阳性局部嗜酸粒细胞和局部lgE结果的患者,但是血清lgE结果为阴性。分类6的患者(19.7%)因高针状得分为特发性鼻炎(IR)患者,但是在局部嗜酸性粒细胞、局部lgE和血清lgE中均为阴性。

最后,研究人员指出,中国的CR患者也许可以分成6种类型,这6种类型具有不同炎症模式,这也许在个性化治疗上具有帮助。

原始出处:

Meng Y, Lou H, Wang Y et al. Endotypes of chronic rhinitis: a cluster analysis study. Allergy. 24 Oct 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1682031, encodeId=d8b216820310b, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Dec 14 00:09:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329173, encodeId=b4ba13291e307, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Nov 11 04:09:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509843, encodeId=6dec1509843e1, content=<a href='/topic/show?id=8fc053e3768' target=_blank style='color:#2F92EE;'>#慢性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53737, encryptionId=8fc053e3768, topicName=慢性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2a10156443, createdName=fyxzlh, createdTime=Sun Nov 11 04:09:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352101, encodeId=125b352101bd, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Nov 10 06:33:22 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352061, encodeId=f4ec3520614f, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Nov 09 19:22:36 CST 2018, time=2018-11-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1682031, encodeId=d8b216820310b, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Dec 14 00:09:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329173, encodeId=b4ba13291e307, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Nov 11 04:09:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509843, encodeId=6dec1509843e1, content=<a href='/topic/show?id=8fc053e3768' target=_blank style='color:#2F92EE;'>#慢性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53737, encryptionId=8fc053e3768, topicName=慢性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2a10156443, createdName=fyxzlh, createdTime=Sun Nov 11 04:09:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352101, encodeId=125b352101bd, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Nov 10 06:33:22 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352061, encodeId=f4ec3520614f, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Nov 09 19:22:36 CST 2018, time=2018-11-09, status=1, ipAttribution=)]
    2018-11-11 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=1682031, encodeId=d8b216820310b, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Dec 14 00:09:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329173, encodeId=b4ba13291e307, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Nov 11 04:09:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509843, encodeId=6dec1509843e1, content=<a href='/topic/show?id=8fc053e3768' target=_blank style='color:#2F92EE;'>#慢性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53737, encryptionId=8fc053e3768, topicName=慢性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2a10156443, createdName=fyxzlh, createdTime=Sun Nov 11 04:09:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352101, encodeId=125b352101bd, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Nov 10 06:33:22 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352061, encodeId=f4ec3520614f, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Nov 09 19:22:36 CST 2018, time=2018-11-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1682031, encodeId=d8b216820310b, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Dec 14 00:09:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329173, encodeId=b4ba13291e307, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Nov 11 04:09:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509843, encodeId=6dec1509843e1, content=<a href='/topic/show?id=8fc053e3768' target=_blank style='color:#2F92EE;'>#慢性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53737, encryptionId=8fc053e3768, topicName=慢性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2a10156443, createdName=fyxzlh, createdTime=Sun Nov 11 04:09:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352101, encodeId=125b352101bd, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Nov 10 06:33:22 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352061, encodeId=f4ec3520614f, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Nov 09 19:22:36 CST 2018, time=2018-11-09, status=1, ipAttribution=)]
    2018-11-10 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1682031, encodeId=d8b216820310b, content=<a href='/topic/show?id=15593040e9a' target=_blank style='color:#2F92EE;'>#内源性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30407, encryptionId=15593040e9a, topicName=内源性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b46b27929604, createdName=diushouji, createdTime=Fri Dec 14 00:09:00 CST 2018, time=2018-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329173, encodeId=b4ba13291e307, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Sun Nov 11 04:09:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509843, encodeId=6dec1509843e1, content=<a href='/topic/show?id=8fc053e3768' target=_blank style='color:#2F92EE;'>#慢性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53737, encryptionId=8fc053e3768, topicName=慢性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d2a10156443, createdName=fyxzlh, createdTime=Sun Nov 11 04:09:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352101, encodeId=125b352101bd, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sat Nov 10 06:33:22 CST 2018, time=2018-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=352061, encodeId=f4ec3520614f, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Fri Nov 09 19:22:36 CST 2018, time=2018-11-09, status=1, ipAttribution=)]
    2018-11-09 天地飞扬

    了解一下,谢谢分享!

    0

相关资讯

Pediatr Allergy Immunol:lgE敏感和鼻炎对炎症生物标记和肺功能的影响

过敏性和非过敏性鼻炎与更差的哮喘控制相关。然而,lgE敏感和/或鼻炎是怎样与肺功能相关的还不清楚。最近,有研究人员评估了鼻炎和敏感对肺功能的影响,包括了患有或不患有哮喘患者的气道系统周边和炎症生物标记情况。研究人员将哮喘、鼻炎和敏感组合的小组与健康的对照进行了比较。研究发现,在只患有哮喘(调整后平均差-2.8%-单位(95% CI -4.7;-1.0), p<0.01))、哮喘和敏感(-2.

Immunotherapy:马齿苋库提取物舌下免疫治疗耐受性和阳性治疗效果研究

最近,有研究人员评估了马齿苋库提取物舌下免疫治疗在患有过敏性鼻窦炎患者的耐受性和治疗效果。研究包括了51名患者,并且进行马齿苋库提取物舌下免疫治疗(6次增加剂量),并且每月对治疗进行调查。研究发现,470给药剂量下,只有3.8%的患者消除了系统性反应(1.5%的非特异性,2.3%的为等级1)。考虑到研究的治疗效果参数,研究人员发现,最后一次的皮肤反应和基线时间点测量的皮肤反应相比,具有显著的降低,

秋季鼻炎 痛苦如“绝症”! 70岁呼吸科老主任教你一招破解

有一种疾病,我国不同程度的患病人群高达3亿人,相当于每4个人就有一个人在饱受折磨。那就是鼻炎。

盘点:鼻炎与治疗

【1】Expert Opin Pharmacother:苯磺酸贝托司汀在永久过敏性鼻炎中的治疗结果分析影响研究苯磺酸贝托司汀(BB)是二代H1抗组胺药物,作为一种滴眼液,在美国是通过FDA批准的可以用于过敏性结膜炎治疗的药物。在其他的国家,口服BB是广泛存在的,主要是用于过敏性鼻炎(AR)以及荨麻疹和慢性瘙痒症状的改善,并且与其他药物治疗的结果类似。最近,有研究人员对文献进行了综合的搜索,这些

盘点:鼻炎研究进展

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】J Agromedicine:美国农场经营者农药的使用、过敏性鼻炎和哮喘情况分析 最近,有研究人员在美国农场经营者中调查了特殊农药的使用与过敏性鼻炎以及哮喘

Eur Ann Allergy Clin Immunol:移动应用apps在过敏性呼吸道疾病中的作用

最近,有研究人员对移动应用在过敏性呼吸道疾病中的作用进行了多中心的调查。他们研究的主要目的是调查在过敏性呼吸道疾病的控制和治疗过程中,移动应用apps的使用和效果情况。研究人员利用包括12个多选问题的调查问卷进行研究,并包括了360名参与者(153名男性和207名女性)。值得注意的是,290名参与者拥有移动手机。120名为个人电脑,68名为平板电脑。123名报道经常使用移动应用apps,209名为